DOC-MEK: a double-blind randomized phase II trial of docetaxel with or without selumetinib in wild-type BRAF advanced melanoma

Gupta A., Love S., Schuh A., Shanyinde M., Larkin JM., Plummer R., Nathan PD., Danson S., Ottensmeier CH., Lorigan P., Collins L., Wise A., Asher R., Lisle R., Middleton MR.

DOI

10.1093/annonc/mdu054

Type

Journal article

Journal

Annals of Oncology

Publisher

Elsevier BV

Publication Date

05/2014

Volume

25

Pages

968 - 974

Permalink Original publication